Cargando…

ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia

Detalles Bibliográficos
Autores principales:	Menezes, J, Salgado, R N, Acquadro, F, Gómez-López, G, Carralero, M C, Barroso, A, Mercadillo, F, Espinosa-Hevia, L, Talavera-Casañas, J G, Pisano, D G, Álvarez, S, Cigudosa, J C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880437/ https://www.ncbi.nlm.nih.gov/pubmed/24212482 http://dx.doi.org/10.1038/bcj.2013.54

Ejemplares similares

CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia
por: Menezes, J, et al.
Publicado: (2013)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
por: Tefferi, A
Publicado: (2010)

Lenalidomide induces degradation of IKZF1 and IKZF3
por: Krönke, Jan, et al.
Publicado: (2014)

Chronic neutrophilic leukemia: a clinical perspective
por: Menezes, Juliane, et al.
Publicado: (2015)

Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3
por: Liu, Xiao-Ping, et al.
Publicado: (2018)

A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation
por: Imataki, Osamu, et al.
Publicado: (2020)

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia
por: Kim, Hyun-Young, et al.
Publicado: (2018)

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
por: Devillier, Raynier, et al.
Publicado: (2015)

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
por: Schönfeld, Lioba, et al.
Publicado: (2022)

ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26
por: Perez Botero, J, et al.
Publicado: (2015)

Trans-Ancestral Fine-Mapping and Epigenetic Annotation as Tools to Delineate Functionally Relevant Risk Alleles at IKZF1 and IKZF3 in Systemic Lupus Erythematosus
por: Vyse, Timothy J., et al.
Publicado: (2020)

P985: THE ALLELIC RATIO OF DRIVER AND ASXL1 MUTATIONS IS PROGNOSTICALLY RELEVANT IN PMF
por: Coltro, G., et al.
Publicado: (2022)

Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3)
por: Ayoub, Maya C., et al.
Publicado: (2023)

Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens.
por: Gangal, S. G., et al.
Publicado: (1979)

Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide
por: Abdulkarim, Haya, et al.
Publicado: (2020)

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia
por: Binder, Moritz, et al.
Publicado: (2022)

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
por: Balasubramani, Anand, et al.
Publicado: (2015)

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion
por: Venn, N C, et al.
Publicado: (2012)

Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis
por: Godoy, C.R.T., et al.
Publicado: (2015)

Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish
por: Gjini, Evisa, et al.
Publicado: (2019)

Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib
por: Angelopoulou, M K, et al.
Publicado: (2016)

ASXL1 and DNMT3A mutation in a cytogenetically normal B3 thymoma
por: Belani, R, et al.
Publicado: (2014)

Functional and cancer genomics of ASXL family members
por: Katoh, M
Publicado: (2013)

ASXL1 plays an important role in erythropoiesis
por: Shi, Hui, et al.
Publicado: (2016)

ASXL1/2 mutations and myeloid malignancies
por: Medina, Edward A., et al.
Publicado: (2022)

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
por: Cui, Yajuan, et al.
Publicado: (2015)

“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms
por: Gleitz, Hélène F.E., et al.
Publicado: (2022)

Hcfc1a regulates neural precursor proliferation and asxl1 expression in the developing brain
por: Castro, Victoria L., et al.
Publicado: (2020)

Identification of germline monoallelic mutations in IKZF2 in patients with immune dysregulation
por: Shahin, Tala, et al.
Publicado: (2022)

Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network
por: Xia, Yu-Kun, et al.
Publicado: (2020)

The clinical impact of IKZF1 mutation in acute myeloid leukemia
por: Zhang, Xiang, et al.
Publicado: (2023)

PB2391: FREQUENCY OF IKZF3 MUTATION IN WALDENSTRÖM’S MACROGLOBULINEMIA
por: Taleb, Assia, et al.
Publicado: (2023)

Knock-down of Kaiso induces proliferation and blocks granulocytic differentiation in blast crisis of chronic myeloid leukemia
por: Cofre, Jaime, et al.
Publicado: (2012)

ASXL1 mutations in Chinese patients with essential thrombocythemia
por: Nie, Yan-Bo, et al.
Publicado: (2018)

Loss of Asxl2 leads to myeloid malignancies in mice
por: Li, Jianping, et al.
Publicado: (2017)

De novo frameshift mutation in ASXL3 in a patient with global developmental delay, microcephaly, and craniofacial anomalies
por: Dinwiddie, Darrell L, et al.
Publicado: (2013)

TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms
por: Soyer, Nur, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9prv8jlaoa3kkda52ue5bsr2du